Explore every episode of the podcast Expert Voices in Dementia

In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this episode, Dr. Schindler provides advice for physicians about communicating biomarker test results with their patients. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this episode, Dr. Schindler presents an overview of factors influencing the selection of cerebrospinal fluid, PET, and blood-based biomarker tests. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dementia care expert, gerontologist, and author, Laura Wayman provides insights into what caregivers for people living with dementia need from healthcare providers and how clinicians can best partner with caregivers. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this episode, Dr. Schindler discusses key factors physicians should consider when ordering a biomarker test and recommendations for how physicians should communicate the need for a particular test with their patients. Learn more about your ad choices. Visit megaphone.fm/adchoices

Joseph M. Volpe, MD, Discipline Director, Clinical Neuroscience, Labcorp, discusses biomarker testing for Alzheimer disease and dementia,, including current offerings, reimbursement, and future directions in this evolving area. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dan Morhaim, MD, board-certified emergency medicine and internal medicine physician, and former 24-year Maryland State Legislator, highlights the importance of discussing end-of-life care issues with dementia patients and best practices for physicians to follow when broaching this topic. Learn more about your ad choices. Visit megaphone.fm/adchoices

Virginia Man-Yee Lee, PhD, who serves as the John H. Ware 3rd Endowed Professor in Alzheimer's Research at the University of Pennsylvania Perelman School of Medicine, the Director of the Center for Neurodegenerative Disease Research, and Co-Director of the Marian S. Ware Center for Alzheimer's Drug Discovery, presents an overview of tau biomarker testing and research. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss recent data analyzing the real-world implications of donanemab treatment for people with Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices

Howard Fillit, MD, geriatrician, neuroscientist, and Chief Science Officer and Co-Founder of the Alzheimer's Drug Discovery Foundation, discusses the importance of research into new therapeutic targets to develop next-generation treatments for Alzheimer disease, including small molecule compounds. Learn more about your ad choices. Visit megaphone.fm/adchoices

George Grossberg, MD, Samuel W. Fordyce Professor and Director of Geriatric Psychiatry, Saint Louis University School of Medicine, provides an overview of recent progress in the evaluation, diagnosis, and treatment of neuropsychiatric symptoms in people living with dementia, including nonpharmacologic and pharmacologic interventions. Learn more about your ad choices. Visit megaphone.fm/adchoices

Lynn D. Kramer, MD, FAAN, Chief Clinical Officer, Deep Human Biology Learning at Eisai and a member of the Eisai Executive Committee, and Christopher van Dyck, MD, Professor of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, provide an overview of key results from the Clarity AD clinical trial assessing the safety and efficacy of lecanemab in people with early Alzheimer disease presented at the 2024 Alzheimer's Association International Conference. Learn more about your ad choices. Visit megaphone.fm/adchoices

Gary E. Gibson, PhD, Professor of Neurosciences, Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, details his research related to metabolic changes associated with Alzheimer disease and a clinical trial studying the effects of benfotiamine therapy on cognitive and other outcomes. Learn more about your ad choices. Visit megaphone.fm/adchoices

Kim Rodriguez, CEO of BrainCheck, provides an overview of the company's cognitive assessment plan and how clinicians can use these tools in practice. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sarena Ho, Health Insurance Specialist at the CMS Innovation Center, provides an overview on the Guiding an Improved Dementia Experience (GUIDE) Model, which helps physicians provide coordinated care to support patients with dementia and their caregivers. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we are joined by entrepreneur and television personality, Barbara Corcoran. While many know Barbara for her business acumen and dynamic presence on Shark Tank, fewer may know the deeply personal and powerful story she shares today—her nine-year journey as a caregiver for her mother, who lived with Alzheimer disease. In this heartfelt conversation, Barbara opens up about the early signs her family overlooked, the emotional toll of watching her mother's personality shift, and the pivotal moment that changed their approach to caregiving. From practical strategies to navigate agitation in Alzheimer disease, to profound lessons in empathy, patience, and family dynamics, Barbara’s story offers inspiration and wisdom for caregivers and physicians. For more information, please visit www.RecognizeAlzheimersAgitation.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sterling Johnson, PhD, Associate Director and Biomarker Core Leader in the Wisconsin Alzheimer’s Disease Research Center (ADRC), and a Clinical Neuropsychologist and Neuroscientist focused on understanding AD-related changes in the brain, details his research into the use of plasma p-tau217 as a blood-based biomarker for detecting Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices

Nicolas Villain, MD, PhD, Associate Professor of Neurology, Sorbonne University, Paris, France, discusses the International Working Group’s updated diagnostic criteria for the diagnosis and staging of Alzheimer disease, which offer an alternative definitional view of AD as a clinical-biologic construct. Learn more about your ad choices. Visit megaphone.fm/adchoices

Timo Grimmer, MD, Associate Professor of Psychiatry and Psychotherapy and Head of the Centre for Cognitive Disorders at the Technical University of Munich, Germany, discusses the experimental oral small molecule drug blarcamesine, which is under investigation as a potential treatment for Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode explores groundbreaking qualitative research from the University of Pennsylvania on patient and caregiver perspectives in Alzheimer disease. Dr. Katie Auriemma, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, and Dr. Carolyn Chow, Penn Medicine, Philadelphia, PA, discuss findings from interviews with patients and caregivers that reveal hopes, worries, and nuanced views on AD therapies—highlighting the importance of patient-centered outcomes, shared decision-making, and aligning treatment with family goals. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ana C. Pereira, MD, Associate Professor, Icahn School of Medicine at Mount Sinai, New York, NY, discusses key takeaways about the impact of patient lifestyle modifications on brain health, updates in biomarkers and disease-modifying therapies, and new frontiers in Alzheimer disease research based on research presented at the 2025 meeting of the Alzheimer’s Association International Conference (AAIC). Learn more about your ad choices. Visit megaphone.fm/adchoices

Gregory E. Cooper, MD, PhD, Director, Memory Center, Norton Neuroscience Institute, Louisville, KY, outlines the Brain Health Navigator program as a strategy to streamline dementia care pathways, ensuring earlier diagnosis and faster access to disease-modifying therapies. This program, developed by the Davos Alzheimer’s Collaborative, is designed to reduce system inefficiencies across primary and specialty care and improve access for all patients. Learn more about your ad choices. Visit megaphone.fm/adchoices

Kyra O'Brien, MD, Assistant Professor of Neurology at the Hospital of the University of Pennsylvania discusses modifiable barriers to performing cognitive evaluations in primary care based on the results of the study, Clinician-reported Factors Influencing Performance of Cognitive Evaluations in Primary Care. Learn more about your ad choices. Visit megaphone.fm/adchoices